4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Average Rating of “Moderate Buy” by Analysts

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) have earned a consensus rating of “Moderate Buy” from the nine ratings firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $47.14.

Several equities research analysts recently issued reports on FDMT shares. Cantor Fitzgerald lowered shares of 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, September 23rd. BMO Capital Markets lowered their price target on shares of 4D Molecular Therapeutics from $63.00 to $40.00 and set an “outperform” rating for the company in a report on Thursday, July 18th. Leerink Partners reissued an “outperform” rating and set a $36.00 price objective (down previously from $40.00) on shares of 4D Molecular Therapeutics in a report on Thursday, September 19th. Royal Bank of Canada restated an “outperform” rating and set a $40.00 price objective on shares of 4D Molecular Therapeutics in a research report on Monday, July 22nd. Finally, Chardan Capital increased their target price on 4D Molecular Therapeutics from $38.00 to $39.00 and gave the company a “buy” rating in a research report on Thursday, September 19th.

Institutional Investors Weigh In On 4D Molecular Therapeutics

A number of institutional investors have recently made changes to their positions in FDMT. nVerses Capital LLC acquired a new position in shares of 4D Molecular Therapeutics in the third quarter worth approximately $40,000. Values First Advisors Inc. bought a new position in 4D Molecular Therapeutics during the 3rd quarter worth approximately $57,000. China Universal Asset Management Co. Ltd. lifted its position in shares of 4D Molecular Therapeutics by 64.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,995 shares of the company’s stock worth $108,000 after purchasing an additional 3,922 shares during the period. Proficio Capital Partners LLC bought a new stake in shares of 4D Molecular Therapeutics in the 3rd quarter valued at $108,000. Finally, Allspring Global Investments Holdings LLC increased its position in shares of 4D Molecular Therapeutics by 702.1% during the first quarter. Allspring Global Investments Holdings LLC now owns 3,457 shares of the company’s stock worth $110,000 after buying an additional 3,026 shares during the period. Institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Stock Down 0.6 %

4D Molecular Therapeutics stock opened at $8.07 on Tuesday. The stock has a market cap of $419.40 million, a PE ratio of -3.51 and a beta of 2.82. 4D Molecular Therapeutics has a 12-month low of $7.90 and a 12-month high of $36.25. The business’s 50-day moving average price is $10.88 and its two-hundred day moving average price is $17.48.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.